Digene shells out $1.6B for Qiagen
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Digene |
Qiagen |
$1.6B acquisition |
Analysts say the acquisition will give Qiagen a leg up in the expanding market for HPV testing. |
|
Schering-Plough |
Novacea |
$440M collaboration pact |
Schering-Plough has agreed to pay $60 million up front and take a stake in Novacea in exchange for commercialization rights to Asentar, a prostate cancer therapy currently in a late-stage trial. |
|
Amgen |
Ilypsa |
$420M acquisition |
Ilypsa is a private biotech that's been developing a new therapy for kidney disease. |
|
Genzyme |
Bioenvision |
$345M buyout |
The two companies co-developed clofarabin in Europe and Genzyme says that it has good reason to believe that the drug has great potential for other cancer indications. |
|
Amgen |
Alantos |
$300M acquisition |
Alantos' lead drug candidate--ALS 2-0426--is a DPP-IV inhibitor in Phase IIa, a popular approach to treating Type 2 diabetes. |